STVN on NYSE

Stevanato Group

Logo: EMompi, CC BY-SA 4.0, via Wikimedia Commons4

Italian multinational company

Stevanato Group is an Italian multinational company headquartered in Piombino Dese, Padua – Italy. Founded in 1949, it is also active in the glass tube forming technology and inspection systems sector.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1.2BRevenue, fiscal 20255
139.8MNet income, fiscal 20255

Compare with another stock.

  • TickerSTVN on NYSE1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersItaly1
  • Founded inVenice1
  • Websitewww.stevanatogroup.com
  • Business addressPiombino Dese (Pd) Via Molinella, 17, Padua, 350176
  • Filer categoryLarge accelerated filer6

Stevanato Group is an Italian multinational company headquartered in Piombino Dese, Padua – Italy.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

29.0%Gross margin5
16.8%Operating margin5
11.8%Net margin5
7.4%Revenue growth, 20255
9.4%Return on equity5
22.3M EURFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Biopharmaceutical And Diagnostic Solutions brought in 79% of the revenue Stevanato Group broke down this way in fiscal 2025.

  1. Biopharmaceutical And Diagnostic Solutions1.0B EUR579%up 11% from 2024
  2. Engineering281.0M EUR521%down 21% from 2024
Business segments by year
Business segments202320242025
Biopharmaceutical And Diagnostic Solutions881.3M EUR937.8M EUR1.0B EUR
Engineering372.8M EUR357.6M EUR281.0M EUR

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue71¢842.4M EUR
  • Research and development2¢25.4M EUR
  • Other costs10¢123.7M EUR
  • Interest0¢5.6M EUR
  • Income tax4¢49.3M EUR
  • Profit12¢139.8M EUR

Out of 1.2B EUR in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending92¢263.8M EUR
  • Dividends paid5¢14.7M EUR
  • Kept or used elsewhere3¢7.6M EUR

Out of 286.1M EUR of cash from operations.5

Financial statements

Revenue89101151.2B EUR in 2025+121% since 2019
0500.0M EUR1.0B EUR1.5B EUR2019: 536.5M EUR536.5M EUR20192020: 662.0M EUR662.0M EUR2020+23%2021: 843.9M EUR843.9M EUR2021+27%2022: 983.7M EUR983.7M EUR2022+17%2023: 1.1B EUR1.1B EUR2023+10%2024: 1.1B EUR1.1B EUR2024+2%2025: 1.2B EUR1.2B EUR2025+7%
Gross profit8910115343.9M EUR in 2025+149% since 2019
0100.0M EUR200.0M EUR300.0M EUR400.0M EUR2019: 138.0M EUR138.0M EUR20192020: 194.2M EUR194.2M EUR2020+41%2021: 265.4M EUR265.4M EUR2021+37%2022: 319.8M EUR319.8M EUR2022+20%2023: 339.9M EUR339.9M EUR2023+6%2024: 302.3M EUR302.3M EUR2024−11%2025: 343.9M EUR343.9M EUR2025+14%
Operating income8910115198.8M EUR in 2025+220% since 2019
0100.0M EUR200.0M EUR300.0M EUR2019: 62.2M EUR62.2M EUR20192020: 103.1M EUR103.1M EUR2020+66%2021: 162.2M EUR162.2M EUR2021+57%2022: 192.4M EUR192.4M EUR2022+19%2023: 200.7M EUR200.7M EUR2023+4%2024: 161.1M EUR161.1M EUR2024−20%2025: 198.8M EUR198.8M EUR2025+23%
Net income8910115139.8M EUR in 2025+261% since 2019
050.0M EUR100.0M EUR150.0M EUR2019: 38.7M EUR38.7M EUR20192020: 78.6M EUR78.6M EUR2020+103%2021: 134.3M EUR134.3M EUR2021+71%2022: 143.0M EUR143.0M EUR2022+7%2023: 145.7M EUR145.7M EUR2023+2%2024: 117.8M EUR117.8M EUR2024−19%2025: 139.8M EUR139.8M EUR2025+19%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenue1.2B EUR1.1B EUR1.1B EUR
Cost of sales842.4M EUR801.7M EUR745.5M EUR
Gross Profit343.9M EUR302.3M EUR339.9M EUR
Other operating income8.2M EUR9.1M EUR10.4M EUR
Selling and marketing expenses28.2M EUR24.9M EUR25.0M EUR
Research and development expenses25.4M EUR31.7M EUR35.7M EUR
General and administrative expenses99.7M EUR93.7M EUR88.9M EUR
Operating Profit198.8M EUR161.1M EUR200.7M EUR
Finance income13.0M EUR13.5M EUR6.8M EUR
Finance expense22.7M EUR14.3M EUR17.9M EUR
Profit Before Tax189.1M EUR160.3M EUR189.6M EUR
Income taxes49.3M EUR42.5M EUR43.9M EUR
Net Profit139.8M EUR117.8M EUR145.7M EUR
Equity holders of the parent139.8M EUR117.8M EUR145.6M EUR
Non-controlling interests-8.0K EUR-12.0K EUR59.0K EUR
Basic earnings per common share (in EUR)0.51 EUR0.43 EUR0.55 EUR
Diluted earnings per common share (in EUR)0.51 EUR0.43 EUR0.55 EUR

Compare Stevanato Group with another company

The story

Nuova Ompi, the first company of the Group, was founded in Venice in 1949 by Giovanni Stevanato, father of the actual president Sergio Stevanato. In 1959 the company moved to its current location: Piombino Dese, Padua – Italy.

A second company (SPAMI) was established in 1971, specialized in the design and construction of high-speed precision machines and complete lines for the production and control of glass tube containers for pharmaceutical use.

In 1993 Stevanato Group purchased Alfamatic (Latina, Italy) and with the acquisition of Medical Glass (Bratislava) in 2005, the Group opened to the internationalization.

In 2007 the Group acquired Optrel (Vicenza), an Italian company specialized in the design and the construction of inspection machines for the pharmaceutical industry. In addition, Nuova Ompi launched the EZ-fill brand, starting with the production of sterile syringes.

In 2008 a new production plant called "Ompi North America" was built in Monterrey, Mexico.

Two years later the EZ-fill concept was extended to vials and cartridges.

In 2012 the Group doubled the Monterrey plant started the construction of a new plant in China (Zhangjiagang - Shanghai area).

In 2013 the Group acquired InnoScan, a Danish manufacturer of inspection machines for the pharmaceutical industry. In 2016 the Group acquired the Danish company SVM Automatik specialized in assembly, packaging and serialization solutions for the pharmaceutical industry and the operative units of Balda Group, specialized in high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. In 2017 the third greenfield - Ompi do Brasil - plant was opened in Sete Lagoas.

From Wikipedia’s article on Stevanato Group, shared under CC BY-SA 4.0.7

Leadership

Who has led Stevanato Group, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Lago Marco Dal2026–now
Board members and other officers (12)

Products and brands

Stevanato Group comprises two operational divisions: Pharmaceutical Systems with Ompi specialized in glass primary packaging and Balda, focused on specialty plastics and delivery devices; Engineering Systems with Spami, Optrel, InnoScan and SVM, specialized in glass processing, inspection systems, assembly, and packaging solutions.

Pharmaceutical Systems Division

With locations throughout the world (Italy, Slovakia, Germany, Mexico, USA, China, Brazil), the Pharmaceutical Systems Division produces traditional products such as vials, ampoules, and also strong growth products such as syringes and cartridges for autoinjection systems.

With the acquisition of the operative units of Balda, the division is also now specialized in plastic solutions, developed and manufactured to meet customers’ specific needs. Balda's healthcare segment is active in diagnostic, pharmaceutical and medical device applications.

Engineering Systems Division

The Engineering Systems Division consists of SPAMI (with its brand Optrel), InnoScan and SVM Automatik.

Read the full text

Spami designs and manufactures machinery for glass tubing converting for the production of vials, cartridges, syringes, ampoules and special devices.

Optrel and InnoScan refer to the visual inspection area focused on the inspection machines market for the pharmaceutical industry.

SVM Automatik is a company specialized in assembly, packaging and serialization solutions for the pharmaceutical industry.

From Wikipedia’s article on Stevanato Group, shared under CC BY-SA 4.0.7

Timeline

  1. Mar 18, 2026New chief executive Franco Stevanato becomes CEO12
  2. Jul 16, 2021Went public Listed on NYSE1

Filings

187 filings to the SEC since October 2021: 6 annual reports, 27 insider forms, 41 large holders, 113 other. The latest 20:

  1. Sep 30, 20264 EDGAR
  2. Sep 14, 2026144 EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 13, 2026SCHEDULE 13G EDGAR
  5. Aug 10, 20264 EDGAR
  6. Aug 10, 20264 EDGAR
  7. Aug 10, 20264 EDGAR
  8. Aug 7, 2026144 EDGAR
  9. Aug 6, 20266-K EDGAR
  10. Aug 4, 2026SCHEDULE 13G EDGAR
  11. Aug 4, 20266-K EDGAR
  12. Aug 4, 20266-K EDGAR
  13. Aug 4, 20266-K EDGAR
  14. Jun 26, 20264 EDGAR
  15. Jun 26, 20264 EDGAR
  16. Jun 26, 20264 EDGAR
  17. Jun 26, 20264 EDGAR
  18. Jun 26, 20264 EDGAR
  19. Jun 26, 20264 EDGAR
  20. Jun 26, 20264 EDGAR

The 187 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 0 buys and 8 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Stocchi MauroSee RemarksSale13,649$21.50$293.5KForm 4
Aug 7, 2026Santel LucianoDirectorSale2,023$20.09$40.6KForm 4
Aug 7, 2026Dal Lago MarcoChief Financial OfficerSale4,209$20.09$84.6KForm 4
Aug 7, 2026Magistretti ElisabettaDirectorSale2,045$20.09$41.1KForm 4
Jun 15, 2026Balachandran MadhavanDirectorSale1,493$17.09$25.5KForm 4
Jun 15, 2026MOREL DONALD E JRDirectorSale1,493$17.09$25.5KForm 4
Jun 15, 2026Flynn KarenDirectorSale1,493$17.09$25.5KForm 4
Jun 15, 2026FEDERICI WILLIAM JDirectorSale1,493$17.09$25.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40